In both the slice preparation as well as in the mouse AD model, the application of senicapoc, an inhibitor of KCa3.1, prevented proinflammatory and hLTP-impairing activities of AβO and neuroinflammation, amyloid load, and improved synaptic plasticity (Jin et al., 2019). Here, ABO is linked to Alzheimer disease.